Nabi Biopharmaceuticals has entered into a five-year commercial manufacturing agreement with Diosynth RTP, Inc. for the manufacture of drug substance for the production of NicVAX, Nabi’s investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse. Diosynth will manufacture the drug substance AMNic-rEPA, which is produced by conjugating nicotine hapten — sourced from another CMO — with the carrier protein rEPA. The resulting drug substance will then...